| Autor: |
Azad TD; 1Department of Neurosurgery, Johns Hopkins Hospital, Baltimore, Maryland; and., Jin MC; 2Stanford University School of Medicine, Stanford, California., Bernhardt LJ; 1Department of Neurosurgery, Johns Hopkins Hospital, Baltimore, Maryland; and., Bettegowda C; 1Department of Neurosurgery, Johns Hopkins Hospital, Baltimore, Maryland; and. |
| Jazyk: |
angličtina |
| Zdroj: |
Neurosurgical focus [Neurosurg Focus] 2020 Jan 01; Vol. 48 (1), pp. E9. |
| DOI: |
10.3171/2019.9.FOCUS19699 |
| Abstrakt: |
Diffuse midline glioma (DMG) is a highly malignant childhood tumor with an exceedingly poor prognosis and limited treatment options. The majority of these tumors harbor somatic mutations in genes encoding histone variants. These recurrent mutations correlate with treatment response and are forming the basis for molecularly guided clinical trials. The ability to detect these mutations, either in circulating tumor DNA (ctDNA) or cerebrospinal fluid tumor DNA (CSF-tDNA), may enable noninvasive molecular profiling and earlier prediction of treatment response. Here, the authors review ctDNA and CSF-tDNA detection methods, detail recent studies that have explored detection of ctDNA and CSF-tDNA in patients with DMG, and discuss the implications of liquid biopsies for patients with DMG. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
